Product Specifications (Leu27) IGF-II:

[Leu27]IGF-II is an analog of human IGF-II which has a Leu(L) substitution in place of Try(Y) at position 27 of the IGF-II amino acid sequence.  Compared to IGF-II,  [Leu27]IGF-II has a 1000- fold reduced affinity for the type 1 receptor.

Source: [Leu27]IGF-II is produced recombinantly in E.coli using a patented expression system, and the [Leu27]IGF-II is refolded under oxidising conditions and a short leader peptide is cleaved. Several chromatography purification steps are employed to yield Receptor Grade [Leu27]IGF-II.

Purity: >95% (as determined by HPLC and N-terminal sequence analysis)

Molecular Weight: 7420 daltons, confirmed by mass spectroscopy

N-terminal sequence analysis of recombinant product:Sequence checked to 27 residues and <95% single sequence.

Biological Activity: [Leu27]IGF-II in a type 2 IGF receptor binding assay using rat L6 myoblasts showed an ED50 of 16 nM, compared to 8 nM for IGF-II.  Compared to IGF-II,[Leu27]IGF-II has a 1000 fold reduced affinity for the type 1 IGFreceptor.

Endotoxin (LAL): <0.01 EU/mg

Stability: At least 2 years at 2-4°C (lyophilised)

Appearance: Lyophilized white powderState: Dried from 0.1M acetic acid:under dry nitrogen at slight vacuum (-25kPa)Reconstitution: Dissolve in dilute acid (e.g. 10mM HCl or 0.1M acetic acid), aliquot and store at -20°C.  For lower dilutions (e.g.<1mg/ml) inclusion of a carrier protein is recommended.  Avoid freeze-thaw cycles. Peptide can be biotinylated by ibt upon request. CAUTION: Not for human or in-vitro diagnostic use! This is a GroPep specification. ibt is authorized distributor of GroPep.

Rev. 2013-02

 Datasheet for (Leu27) IGF-II, recombinant protein (Receptor Grade)